Latest Insights

Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer

Following its recent expansion into Japan, Lantern Pharma has now dosed the first patient in Taiwan as part of its Phase 2 Harmonic clinical trial., evaluating LP-300 in never-smoker non-small …

Continue ›››

IDEAYA Demonstrates Preclinical Success with PRMT5 Inhibitor IDE892

IDEAYA Biosciences, Inc. (Nasdaq: IDYA), a clinical-stage precision medicine oncology company, announced the nomination of IDE892, a potent and selective MTA-cooperative PRMT5 inhibitor, as its latest development candidate. IDE892 is …

Continue ›››

Cherry Biotech Publishes Research on Advanced Skin-on-Chip Model in Microfluidics

Cherry Biotech has announced the publication of research on its CubiX platform in Advanced Healthcare Materials. The study explores a microfluidic system designed to replicate key features of human skin, …

Continue ›››

Antag Therapeutics Secures €80 Million to Advance GIPR-Based Obesity Therapies

Following the FDA’s October 2024 clearance of Antag Therapeutics’ Investigational New Drug (IND) application for its lead molecule, AT-7687, the Copenhagen-based biopharmaceutical company has announced the successful closing of an …

Continue ›››

AI Proteins Announces Collaboration with Bristol Myers Squibb for Miniprotein Therapeutics Worth Up to $400 Million

AI Proteins, Inc., a biotechnology company specializing in the computational design of therapeutic miniproteins, announced a research collaboration and option agreement with Bristol Myers Squibb (NYSE: BMY). The partnership aims …

Continue ›››

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Rare Diseases and Oncology

Unnatural Products, Inc. a California-based biotech company specializing in AI-enabled massively parallel chemistry to develop orally bioavailable macrocyclic peptides, announced that BridgeBio Pharma, Inc. has exercised its option to license …

Continue ›››

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics from Sumitomo Chemical

GE HealthCare (NASDAQ: GEHC) announced an agreement to acquire Sumitomo Chemical’s 50% stake in Nihon Medi-Physics Co., Ltd. (NMP), assuming full ownership of the Japanese radiopharmaceutical company. The deal, subject …

Continue ›››

Recursion Begins First-in-Human Trial for AI-Discovered Protein Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

In October 2024, Recursion Pharmaceuticals received FDA clearance to initiate clinical trials for REC-1245, an investigational RBM39 degrader targeting biomarker-enriched solid tumors and lymphoma. Now, just two months later, the …

Continue ›››

Lantern Pharma Enrolls First Patient in Taiwan for Phase 2 Trial for Never-Smoker Lung Cancer

IDEAYA Demonstrates Preclinical Success with PRMT5 Inhibitor IDE892

Cherry Biotech Publishes Research on Advanced Skin-on-Chip Model in Microfluidics

Antag Therapeutics Secures €80 Million to Advance GIPR-Based Obesity Therapies

AI Proteins Announces Collaboration with Bristol Myers Squibb for Miniprotein Therapeutics Worth Up to $400 Million

Unnatural Products Announces BridgeBio Exercises Option to License Macrocyclic Therapeutics for Rare Diseases and Oncology

GE HealthCare to Acquire Full Ownership of Nihon Medi-Physics from Sumitomo Chemical

Recursion Begins First-in-Human Trial for AI-Discovered Protein Degrader for Biomarker-Enriched Solid Tumors and Lymphoma

Insilico Medicine Celebrates Its 10th AI-Driven Drug Candidate to Get FDA IND Clearance

Brainomix Wins Two Awards for AI Imaging Technology

Raidium Secures €16 Million to Advance Radiology Foundation Model

Wyss Institute’s iNodes Team Secures ARPA-H Award to Advance Implantable Immune Organs for Ovarian Cancer Treatment